Phase II trial of combination chemotherapy with cisplatin, carboplatin and etoposide in stage IIIB and IV small-cell lung cancer

Yoichi Nakanishi, Yuji Kawarada, Nobuyuki Hirose, Kiyoshi Ninomiya, Masayuki Miyazaki, Naoki Miyazaki, Yukio Kurita, Hideaki Kanegae, Osamu Ohgushi, Kenichi Ogata, Hiroshi Yamazaki, Satoru Inutsuka, Nobuyuki Hara

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Purpose: A phase II trial combining cisplatin, carboplatin and etoposide was conducted in previously untreated patients with stage IIIB and IV small-cell lung cancer, in an attempt to increase response rates and prolong survival. Methods: Previously untreated patients with small-cell lung cancer, with measurable disease, aged ≤72 years, performance status ≤2, and adequate hematologic, hepatic and renal function were enrolled in the study. They were treated with 80 mg/m2 cisplatin on day 1, 100 mg/m2 carboplatin on days 2, 3 and 8, and 50 mg/m2 etoposide on days 1, 2, 3 and 8. Results: A total of 46 patients (20 with stage IIIB and 26 with stage IV disease) were enrolled in the study. A total of 186 courses of chemotherapy were given, and the dose was reduced in 27 courses (15%). The chemotherapy was repeated for four or more courses in 30 patients. There were 10 complete responses and 32 partial responses, for a total response rate of 91% (95% confidence interval, 79% to 98%). The median survival time and 2-year survival rates were 18 months and 22% for stage IIIB disease, and 14 months and 15% for stage IV disease. Major side effects were hematologic: leukopenia, anemia, and thrombocytopenia of grade 3 or more occurred in 48%, 46%, and 43% of patients, respectively. Conclusions: The three-drug regimen of cisplatin, carboplatin and etoposide is feasible and active against small-cell lung cancer.

Original languageEnglish
Pages (from-to)453-456
Number of pages4
JournalCancer chemotherapy and pharmacology
Volume41
Issue number6
DOIs
Publication statusPublished - Apr 8 1998

Fingerprint

Chemotherapy
Carboplatin
Small Cell Lung Carcinoma
Etoposide
Combination Drug Therapy
Cisplatin
Cells
Survival Rate
Drug Therapy
Leukopenia
Anemia
Confidence Intervals
Kidney
Pharmaceutical Preparations
Survival
Liver

All Science Journal Classification (ASJC) codes

  • Oncology
  • Toxicology
  • Pharmacology
  • Cancer Research
  • Pharmacology (medical)

Cite this

Phase II trial of combination chemotherapy with cisplatin, carboplatin and etoposide in stage IIIB and IV small-cell lung cancer. / Nakanishi, Yoichi; Kawarada, Yuji; Hirose, Nobuyuki; Ninomiya, Kiyoshi; Miyazaki, Masayuki; Miyazaki, Naoki; Kurita, Yukio; Kanegae, Hideaki; Ohgushi, Osamu; Ogata, Kenichi; Yamazaki, Hiroshi; Inutsuka, Satoru; Hara, Nobuyuki.

In: Cancer chemotherapy and pharmacology, Vol. 41, No. 6, 08.04.1998, p. 453-456.

Research output: Contribution to journalArticle

Nakanishi, Y, Kawarada, Y, Hirose, N, Ninomiya, K, Miyazaki, M, Miyazaki, N, Kurita, Y, Kanegae, H, Ohgushi, O, Ogata, K, Yamazaki, H, Inutsuka, S & Hara, N 1998, 'Phase II trial of combination chemotherapy with cisplatin, carboplatin and etoposide in stage IIIB and IV small-cell lung cancer', Cancer chemotherapy and pharmacology, vol. 41, no. 6, pp. 453-456. https://doi.org/10.1007/s002800050766
Nakanishi, Yoichi ; Kawarada, Yuji ; Hirose, Nobuyuki ; Ninomiya, Kiyoshi ; Miyazaki, Masayuki ; Miyazaki, Naoki ; Kurita, Yukio ; Kanegae, Hideaki ; Ohgushi, Osamu ; Ogata, Kenichi ; Yamazaki, Hiroshi ; Inutsuka, Satoru ; Hara, Nobuyuki. / Phase II trial of combination chemotherapy with cisplatin, carboplatin and etoposide in stage IIIB and IV small-cell lung cancer. In: Cancer chemotherapy and pharmacology. 1998 ; Vol. 41, No. 6. pp. 453-456.
@article{1ef083efac91442e945d72f194c7ac57,
title = "Phase II trial of combination chemotherapy with cisplatin, carboplatin and etoposide in stage IIIB and IV small-cell lung cancer",
abstract = "Purpose: A phase II trial combining cisplatin, carboplatin and etoposide was conducted in previously untreated patients with stage IIIB and IV small-cell lung cancer, in an attempt to increase response rates and prolong survival. Methods: Previously untreated patients with small-cell lung cancer, with measurable disease, aged ≤72 years, performance status ≤2, and adequate hematologic, hepatic and renal function were enrolled in the study. They were treated with 80 mg/m2 cisplatin on day 1, 100 mg/m2 carboplatin on days 2, 3 and 8, and 50 mg/m2 etoposide on days 1, 2, 3 and 8. Results: A total of 46 patients (20 with stage IIIB and 26 with stage IV disease) were enrolled in the study. A total of 186 courses of chemotherapy were given, and the dose was reduced in 27 courses (15{\%}). The chemotherapy was repeated for four or more courses in 30 patients. There were 10 complete responses and 32 partial responses, for a total response rate of 91{\%} (95{\%} confidence interval, 79{\%} to 98{\%}). The median survival time and 2-year survival rates were 18 months and 22{\%} for stage IIIB disease, and 14 months and 15{\%} for stage IV disease. Major side effects were hematologic: leukopenia, anemia, and thrombocytopenia of grade 3 or more occurred in 48{\%}, 46{\%}, and 43{\%} of patients, respectively. Conclusions: The three-drug regimen of cisplatin, carboplatin and etoposide is feasible and active against small-cell lung cancer.",
author = "Yoichi Nakanishi and Yuji Kawarada and Nobuyuki Hirose and Kiyoshi Ninomiya and Masayuki Miyazaki and Naoki Miyazaki and Yukio Kurita and Hideaki Kanegae and Osamu Ohgushi and Kenichi Ogata and Hiroshi Yamazaki and Satoru Inutsuka and Nobuyuki Hara",
year = "1998",
month = "4",
day = "8",
doi = "10.1007/s002800050766",
language = "English",
volume = "41",
pages = "453--456",
journal = "Cancer Chemotherapy and Pharmacology",
issn = "0344-5704",
publisher = "Springer Verlag",
number = "6",

}

TY - JOUR

T1 - Phase II trial of combination chemotherapy with cisplatin, carboplatin and etoposide in stage IIIB and IV small-cell lung cancer

AU - Nakanishi, Yoichi

AU - Kawarada, Yuji

AU - Hirose, Nobuyuki

AU - Ninomiya, Kiyoshi

AU - Miyazaki, Masayuki

AU - Miyazaki, Naoki

AU - Kurita, Yukio

AU - Kanegae, Hideaki

AU - Ohgushi, Osamu

AU - Ogata, Kenichi

AU - Yamazaki, Hiroshi

AU - Inutsuka, Satoru

AU - Hara, Nobuyuki

PY - 1998/4/8

Y1 - 1998/4/8

N2 - Purpose: A phase II trial combining cisplatin, carboplatin and etoposide was conducted in previously untreated patients with stage IIIB and IV small-cell lung cancer, in an attempt to increase response rates and prolong survival. Methods: Previously untreated patients with small-cell lung cancer, with measurable disease, aged ≤72 years, performance status ≤2, and adequate hematologic, hepatic and renal function were enrolled in the study. They were treated with 80 mg/m2 cisplatin on day 1, 100 mg/m2 carboplatin on days 2, 3 and 8, and 50 mg/m2 etoposide on days 1, 2, 3 and 8. Results: A total of 46 patients (20 with stage IIIB and 26 with stage IV disease) were enrolled in the study. A total of 186 courses of chemotherapy were given, and the dose was reduced in 27 courses (15%). The chemotherapy was repeated for four or more courses in 30 patients. There were 10 complete responses and 32 partial responses, for a total response rate of 91% (95% confidence interval, 79% to 98%). The median survival time and 2-year survival rates were 18 months and 22% for stage IIIB disease, and 14 months and 15% for stage IV disease. Major side effects were hematologic: leukopenia, anemia, and thrombocytopenia of grade 3 or more occurred in 48%, 46%, and 43% of patients, respectively. Conclusions: The three-drug regimen of cisplatin, carboplatin and etoposide is feasible and active against small-cell lung cancer.

AB - Purpose: A phase II trial combining cisplatin, carboplatin and etoposide was conducted in previously untreated patients with stage IIIB and IV small-cell lung cancer, in an attempt to increase response rates and prolong survival. Methods: Previously untreated patients with small-cell lung cancer, with measurable disease, aged ≤72 years, performance status ≤2, and adequate hematologic, hepatic and renal function were enrolled in the study. They were treated with 80 mg/m2 cisplatin on day 1, 100 mg/m2 carboplatin on days 2, 3 and 8, and 50 mg/m2 etoposide on days 1, 2, 3 and 8. Results: A total of 46 patients (20 with stage IIIB and 26 with stage IV disease) were enrolled in the study. A total of 186 courses of chemotherapy were given, and the dose was reduced in 27 courses (15%). The chemotherapy was repeated for four or more courses in 30 patients. There were 10 complete responses and 32 partial responses, for a total response rate of 91% (95% confidence interval, 79% to 98%). The median survival time and 2-year survival rates were 18 months and 22% for stage IIIB disease, and 14 months and 15% for stage IV disease. Major side effects were hematologic: leukopenia, anemia, and thrombocytopenia of grade 3 or more occurred in 48%, 46%, and 43% of patients, respectively. Conclusions: The three-drug regimen of cisplatin, carboplatin and etoposide is feasible and active against small-cell lung cancer.

UR - http://www.scopus.com/inward/record.url?scp=6844252897&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=6844252897&partnerID=8YFLogxK

U2 - 10.1007/s002800050766

DO - 10.1007/s002800050766

M3 - Article

C2 - 9554588

AN - SCOPUS:6844252897

VL - 41

SP - 453

EP - 456

JO - Cancer Chemotherapy and Pharmacology

JF - Cancer Chemotherapy and Pharmacology

SN - 0344-5704

IS - 6

ER -